R von Moos
Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.
Mark M, Rusakiewicz S, Früh M, Hayoz S, Grosso F, Pless M, Zucali P, Ceresoli G, Maconi A, Schneider M, Froesch P, Tarussio D, Benedetti F, Dagher J, Kandalaft L, von Moos R, Tissot-Renaud S, Schmid S, Metaxas Y. Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study. ESMO Open 2022; 7:100446.
12.04.2022Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.
12.04.2022ESMO Open 2022; 7:100446
Mark M, Rusakiewicz S, Früh M, Hayoz S, Grosso F, Pless M, Zucali PA, Ceresoli G L, Maconi A, Schneider M, Froesch P, Tarussio D, Benedetti F, Dagher J, Kandalaft L, von Moos R, Tissot-Renaud S, Schmid S, Metaxas Y
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)
Metaxas Y, von Moos R, Rauch D, Appenzeller C, Waibel C, Schmid S, Froesch P, Biaggi-Rudolf C, Perrino M, Maconi A, Schneider M, Mark M, Ceresoli G, Zucali P, Pless M, Grosso F, Eboulet E, Früh M, Swiss Group for Clinical Cancer Research (SAKK). Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16). Ann Oncol 2020; 31:495-500.
16.01.2020Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)
16.01.2020Ann Oncol 2020; 31:495-500
Metaxas Y, von Moos R, Rauch D, Appenzeller Christina, Waibel C, Schmid S, Froesch P, Biaggi-Rudolf C, Perrino M, Maconi A, Schneider M, Mark M, Ceresoli G L, Zucali P A, Pless M, Grosso F, Eboulet E I, Früh Martin, Swiss Group for Clinical Cancer Research (SAKK)
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial
Wirsching H, Riklin C, Felsberg J, Roth P, Jones D, Pfister S, Rushing E, Abrey L, Reifenberger G, Held L, von Deimling A, Ochsenbein A, von Moos R, Caparrotti F, Tabatabai G, Roelcke U, Hottinger A, Jörger F, Schmid A, Plasswilm L, Schrimpf D, Mancao C, Capper D, Conen K, Hundsberger T, Weller M. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. Ann Oncol 2018; 29:1423-1430.
01.06.2018Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial
01.06.2018Ann Oncol 2018; 29:1423-1430
Wirsching H-G, Riklin C, Felsberg J, Roth P, Jones D T W, Pfister S, Rushing E J, Abrey L, Reifenberger G, Held L, von Deimling A, Ochsenbein A, von Moos R, Caparrotti F, Tabatabai G, Roelcke U, Hottinger A F, Jörger F, Schmid A, Plasswilm Ludwig, Schrimpf D, Mancao C, Capper D, Conen K, Hundsberger Thomas, Weller M
A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial
Gennari A, Bernhard J, Morales S, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan M, Ribi K, Amillano Parraga K, Walshe J, Sun Z, Hasler-Strub U, Colleoni M, Kennedy M, von Moos R, Cortes J, Vidal M, Hennessy B, Jerusalem G. A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. Ann Oncol 2017
08.12.2017A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial
08.12.2017Ann Oncol 2017
Gennari A, Bernhard J, Morales S Murillo, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan M M, Ribi K, Amillano Parraga K, Walshe J, Sun Z, Hasler-Strub Ursula, Colleoni M, Kennedy M J, von Moos R, Cortes J, Vidal M J, Hennessy B, Jerusalem G
Absence of Evidence is not Evidence of Absence: The Case of Non-Inferiority
Klingbiel D, Thürlimann B, Brauchli P, von Moos R. Absence of Evidence is not Evidence of Absence: The Case of Non-Inferiority. Ann Oncol 2017
31.08.2017Absence of Evidence is not Evidence of Absence: The Case of Non-Inferiority
31.08.2017Ann Oncol 2017
Klingbiel D, Thürlimann Beat, Brauchli P, von Moos R
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors
Stathis A, Sessa C, Gargiulo P, Berardi S, Enoiu M, Xyrafas A, Catapano C, Allegrini S, Ackermann C, Mark M, Jörger M, Griguolo G, Homicsko K, von Moos R, Hess D, Swiss Group for Clinical Cancer Research (SAKK). Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors. Invest New Drugs 2017; 35:766-772.
20.03.2017Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors
20.03.2017Invest New Drugs 2017; 35:766-772
Stathis A, Sessa C, Gargiulo P, Berardi S, Enoiu M, Xyrafas A, Catapano C V, Allegrini S, Ackermann C J, Mark M, Jörger Markus, Griguolo G, Homicsko K, von Moos R, Hess Dagmar, Swiss Group for Clinical Cancer Research (SAKK)
The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06)
Strasser F, Koeberle D, Kaasa S, Mauri S, Haefner M, Brauchli P, Klingbiel D, Hayoz S, Betticher D, Aebi S, Ribi K, Cathomas R, von Moos R, Blum D, Swiss Group for Clinical Cancer Research (SAKK). The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06). Ann Oncol 2015
08.12.2015The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06)
08.12.2015Ann Oncol 2015
Strasser Florian, Koeberle D, Kaasa S, Mauri S, Haefner M, Brauchli P, Klingbiel D, Hayoz S, Betticher D, Aebi S, Ribi K, Cathomas R, von Moos R, Blum D, Swiss Group for Clinical Cancer Research (SAKK)
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
Koeberle D, Kollar A, Saletti P, Roth A, Früh M, Kueng M, Popescu R, Schacher S, Hess V, Moosmann P, Anchisi S, Betticher D, von Moos R, Dietrich D, Brauchli P, Baertschi D, Matter K, Winterhalder R, Borner M, Herrmann R. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Ann Oncol 2015; 26:709-14.
20.01.2015Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
20.01.2015Ann Oncol 2015; 26:709-14
Koeberle D, Kollar A, Saletti P, Roth A, Früh Martin, Kueng M, Popescu R A, Schacher S, Hess V, Moosmann P, Anchisi S, Betticher D C, von Moos R, Dietrich D, Brauchli P, Baertschi D, Matter K, Winterhalder R, Borner M, Herrmann R
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)
Jörger M, Zappa F, Klingbiel D, Brauchli P, Rothschild S, Gautschi O, Pless M, Ochsenbein A, von Moos R, Betticher D, Stahel R, Droege C, Früh M, Baty F, Brutsche M. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung Cancer 2014; 85:306-13.
29.05.2014Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)
29.05.2014Lung Cancer 2014; 85:306-13
Jörger Markus, Zappa F, Klingbiel D, Brauchli P, Rothschild S, Gautschi O, Pless M, Ochsenbein A, von Moos R, Betticher D C, Stahel R A, Droege C, Früh Martin, Baty Florent, Brutsche Martin
Feasibility and acceptance of electronic monitoring of symptoms and syndromes using a handheld computer in patients with advanced cancer in daily oncology practice
Blum D, Strasser F, Kaasa S, Hayoz S, Dewolf-Linder S, Mingrone W, von Moos R, Walker J, Omlin A, Koeberle D, Ribi K. Feasibility and acceptance of electronic monitoring of symptoms and syndromes using a handheld computer in patients with advanced cancer in daily oncology practice. Support Care Cancer 2014; 22:2425-34.
05.04.2014Feasibility and acceptance of electronic monitoring of symptoms and syndromes using a handheld computer in patients with advanced cancer in daily oncology practice
05.04.2014Support Care Cancer 2014; 22:2425-34
Blum D, Strasser Florian, Kaasa S, Hayoz S, Dewolf-Linder S, Mingrone W, von Moos R, Walker J, Omlin Aurelius, Koeberle D, Ribi K
Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort
Cathomas R, von Moos R, Nagaraj N, Simmonds P, Wheater M, Ellis S, Mead G, Geldart T, Klingbiel D, Fehr M. Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort. Ann Oncol 2014; 25:1591-7.
25.03.2014Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort
25.03.2014Ann Oncol 2014; 25:1591-7
Cathomas R, von Moos R, Nagaraj N, Simmonds P, Wheater M, Ellis S, Mead G M, Geldart T R, Klingbiel D, Fehr Martin
Dyspnoea and a lung mass in a young female 2 weeks after Caesarean delivery
Schwitter M, Potocnik P, von Moos R, Frick H, Furrer M, Cathomas R. Dyspnoea and a lung mass in a young female 2 weeks after Caesarean delivery. Eur Respir J. 2011; 38:465-7.
01.08.2011Dyspnoea and a lung mass in a young female 2 weeks after Caesarean delivery
01.08.2011Eur Respir J. 2011; 38:465-7
Schwitter M, Potocnik Primoz, von Moos R, Frick H, Furrer M, Cathomas R
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)
von Moos R, Dummer R, Schönewolf N, Mamot C, Mjhic-Probst D, Schraml P, Moch H, Schläppi M, Cathomas R, Michielin O, Ochsenbein A, Gillessen S, Goldinger S, Simcock M, Seifert B, on behaalf of the Swiss Group for Clinical Cancer Research (SAKK). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol 2011; 23:531-6.
28.04.2011First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)
28.04.2011Ann Oncol 2011; 23:531-6
von Moos R, Dummer R, Schönewolf N, Mamot C, Mjhic-Probst D, Schraml P H, Moch H, Schläppi M, Cathomas R, Michielin O, Ochsenbein A, Gillessen S, Goldinger S M, Simcock M, Seifert B, on behaalf of the Swiss Group for Clinical Cancer Research (SAKK)
Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03)
Köberle D, Thürlimann B, Pilop C, Crowe S, Öhlschlegel C, von Moos R, Zaman K, Pagani O, Jost L, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK). Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). Endocr Relat Cancer 2011; 18:257-64.
09.03.2011Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03)
09.03.2011Endocr Relat Cancer 2011; 18:257-64
Köberle Dieter, Thürlimann Beat, Pilop C, Crowe S, Öhlschlegel Christian, von Moos R, Zaman K, Pagani O, Jost L, Ruhstaller Thomas, Swiss Group for Clinical Cancer Research (SAKK)
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
Rochlitz C, Zaman K, Mayer M, Cliffe B, Herrmann R, Mannhart-Harms M, Muller A, Rauch D, Winterhalder R, von Moos R, Schonenberger A, Fehr M, Bühlmann M, Suter T, Huober J, Spirig C, Lerch S, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Ann Oncol 2010; 22:80-5.
01.07.2010Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
01.07.2010Ann Oncol 2010; 22:80-5
Rochlitz C, Zaman K, Mayer M, Cliffe B, Herrmann R, Mannhart-Harms M, Muller A, Rauch D, Winterhalder R, von Moos R, Schonenberger A, Fehr M, Bühlmann M, Suter T, Huober Jens, Spirig C, Lerch S, Ruhstaller Thomas, Swiss Group for Clinical Cancer Research (SAKK)
Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)
Ruhstaller T, Popescu R, Bodis S, Schnider A, Terraciano L, Köberle D, Balmermajno S, Pestalozzi B, Borner M, von Moos R, Mingrone W, Hess V, Roth A, Schuller J, Widmer L, Swiss Group for Clinical Cancer Research (SAKK). Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009; 20:1522-8.
01.09.2009Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)
01.09.2009Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009; 20:1522-8
Ruhstaller Thomas, Popescu R, Bodis S, Schnider A, Terraciano L, Köberle Dieter, Balmermajno S, Pestalozzi B C, Borner M, von Moos R, Mingrone W, Hess V, Roth A, Schuller J C, Widmer L, Swiss Group for Clinical Cancer Research (SAKK)
A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03
Hitz F, Ghielmini M, Zimmermann D, Bertoni F, Cogliatti S, Peterson J, Simcock M, Mingrone W, von Moos R, Zucca E, Martinelli G, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. Hematological oncology 2009; 27:154-9.
01.09.2009A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03
01.09.2009Hematological oncology 2009; 27:154-9
Hitz Felicitas, Ghielmini M, Zimmermann D R, Bertoni F, Cogliatti Sergio B., Peterson J, Simcock M, Mingrone W, von Moos R, Zucca E, Martinelli G, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
Borner M, Mingrone W, Lanz D, Dietrich D, Kappeler A, Roth A, Ruhstaller T, Caspar C, Pestalozzi B, Helbling D, Trojan A, Hess V, Rauch D, Saletti P, von Moos R, Koeberle D, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008; 19:1288-92.
01.07.2008Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
01.07.2008Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008; 19:1288-92
Borner M, Mingrone W, Lanz D, Dietrich D, Kappeler A, Roth A, Ruhstaller Thomas, Caspar C, Pestalozzi B, Helbling D, Trojan A, Hess V, Rauch D, Saletti P, von Moos R, Koeberle D, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study
von Moos R, Caspar C, Thürlimann B, Angst R, Inauen R, Greil R, Bergstrom B, Schmieding K, Pecherstorfer M. Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study. Ann Oncol 2008; 19:1266-70.
01.07.2008Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study
01.07.2008Ann Oncol 2008; 19:1266-70
von Moos R, Caspar C B, Thürlimann Beat, Angst Rahel, Inauen Roman, Greil R, Bergstrom B, Schmieding K, Pecherstorfer M
Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer
Köberle D, Rust C, Bieri G, Neuweiler J, Terraciano L, Ruhstaller T, Heitzmann F, Hess V, Winterhalder R, von Moos R, Burkhard R, Toepfer M. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. British journal of cancer 2008; 98:1204-9.
08.04.2008Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer
08.04.2008British journal of cancer 2008; 98:1204-9
Köberle Dieter, Rust C, Bieri G, Neuweiler Jörg, Terraciano L, Ruhstaller Thomas, Heitzmann F, Hess V, Winterhalder R, von Moos R, Burkhard R, Toepfer M